Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat inflammatory pain, but they can have severe side effects, including potentially life-threatening gastrointestinal, renal and cardiac toxicity. Their analgesic effect is driven by inhibition of prostaglandin (PG) biosynthesis and subsequent inflammation, but this inhibitory effect on inflammation could delay pain resolution. An optimal approach to managing PG-mediated pain would selectively relieve pain while preserving the PGs’ essential inflammatory and protective functions.

Activating Toll-like receptors (TLRs) with agonists can promote pro-inflammatory responses mediated by the adaptor protein MyD88 and the downstream effector NF-κB, and these responses can inhibit tumor growth.

Angelman syndrome is a rare genetic, nondegenerative and neurodevelopmental disorder caused by mutations affecting the expression of maternal UBE3A, which is expressed in neurons and is a key protein for neuronal morphology and correct synaptic functioning. The disease is characterized by intellectual disability, defects in movement and sleep disruption, among others.

Sichuan Biokin Pharmaceutical Co. Ltd. has gained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials with [177Lu]-BL-ARC001 injection.

Ascletis Pharma Inc. has selected ASC-35, a once-monthly, subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual peptide agonist, as a clinical development candidate. Ascletis expects to submit an IND application to the FDA for ASC-35 for the treatment of obesity in the second quarter of next year.